Loading…
← CockpitCompetitor Analysis › 600479.SS Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A600479.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 86
Mkt cap
$746M
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$25.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+3.8 pp
WACC 6.8%
Hurdle
-2 pp
Req g minus delivered
Close · CNYCN¥10.11
1D-0.9%
1W-5.6%
1M-8.4%
3M+1.2%
6M-2.6%
YTD-0.5%
1Y-5.6%
ATR %3.9%
52w lowhigh33.7% off high

What Zhuzhou Qianjin Pharmaceutical does

Employees: 5,041

Zhuzhou Qianjin Pharmaceutical at a glance

Size Zhuzhou Qianjin Pharmaceutical (600479.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $746M, the 2740th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.11 on 18 Nov 2026.

Performance Over six months the shares fell 2.6%, against -19.7% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 3.5% over the last twelve months (peer median +2.8%); the operating margin is 11.0% (peer median 9.5%).

Valuation It trades at 1.4× enterprise value to sales against a peer median of 2.5× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.8 points above its cost of capital (6.8% WACC).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026600479.SS 99Peer median 82
Six months, rebased to 100: Zhuzhou Qianjin Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhuzhou Qianjin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.75BCN¥3.60BCN¥3.59BCN¥3.77BCN¥4.00B
Revenue growth—0%-5%-6%—
Gross profitCN¥1.88BCN¥1.71BCN¥1.61BCN¥1.69BCN¥1.68B
EBITDAn/aCN¥483MCN¥401MCN¥498MCN¥517M
Net incomeCN¥357MCN¥286MCN¥231MCN¥320MCN¥303M
Free cash flowCN¥360MCN¥361MCN¥357MCN¥410MCN¥725M
Capital expenditureCN¥142MCN¥124MCN¥47.3MCN¥44.0MCN¥34.4M
Total debtCN¥561MCN¥559MCN¥407MCN¥560MCN¥700M

Quarterly statements and history in the cockpit →

Zhuzhou Qianjin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%21710029073007050024243001LXRX600530688799002390SGMTBLISSGVS4534ARDX600479.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhuzhou Qianjin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×217100290730070500242421863001LXRX688566600530002390603998BLISSGVS05704534ARDX600479.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhuzhou Qianjin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%00290730070500242421863001688566600530002390603998BLISSGVS002349600479.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhuzhou Qianjin Pharmaceutical is the large dot.

Zhuzhou Qianjin Pharmaceutical competitors and peer comparison

How Zhuzhou Qianjin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhuzhou Qianjin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600479.SSPeer medianRank in peer set
1-month return-8.4%-4.5%9th lowest of 20
6-month return-2.6%-19.7%5th highest of 20
Distance from 52-week high-33.7%-34.2%10th highest of 20
Revenue growth (TTM)+3.5%+2.8%9th highest of 20
Operating margin11.0%9.5%8th highest of 20
EV / Sales1.4×2.5×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)-2.1%0.3%5th least demanding of 12
Growth delivered (Del g)0.0%+1.9%5th lowest of 12
Hurdle (Req g minus delivered)-2.0 pp-3.1 pp6th most demanding of 12
ROIC minus cost of capital+3.8 pp+0.0 pp6th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%0.8×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%

Questions

Which companies are Zhuzhou Qianjin Pharmaceutical's closest peers?
The cockpit's peer set: CARsgen Therapeutics (2171.HK), Chongqing Pharscin Pharmaceutical (002907.SZ), Hunan Jiudian Pharmaceutical (300705.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Luye Pharma (2186.HK), Katakura Industries (3001.T), Lexicon Pharmaceuticals (LXRX), Jiangsu Jibeier Pharmaceutical (688566.SS).
Is Zhuzhou Qianjin Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.4× against a peer median of 2.5×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has Zhuzhou Qianjin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -2.6% against -19.7% for the median peer; over one year -5.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.